Amgen Inc () has held its Q1 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks. Unlock hedge fund-level data and powerful investing tools for smar ...

Amgen stock toppled Friday as investors digested its "generally in-line" first-quarter report and expansion in the obesity treatment space.

AMGN beats Q1 estimates as 16 drugs post double-digit growth, offsetting biosimilar erosion and weaker legacy products while lifting 2026 outlook.

Unfavorable lipid profiles are becoming a larger concern in primary care. A noted increase in dyslipidemia among children and ...

Amgen has launched a late-stage program to test the feasibility of switching patients from weekly GLP-1 injections to its own ...

Moby Strategic Performance and Portfolio Evolution. Management characterizes 2026 as a 'springboard year' where rapid growth ...

Amgen CEO Robert Bradway has declared 2026 a “springboard year” for the California big biotech, in which the growth of its ...

Amgen Inc (AMGN) reports a robust 4% growth in product sales, driven by key growth drivers, while navigating patent expirations and increased competition.

Amgen on Thursday reported first-quarter product sales rose 4%, helped by demand for cholesterol and rare disease medicines, ...

While the top- and bottom-line numbers for Amgen (AMGN) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to ...

Good afternoon, everyone, and welcome to our first quarter of 2026 earnings call. Bob Bradway will lead the call today and be followed by a broader review of our performance by Murdo Gordon, Jay ...

Amgen on Thursday reported first-quarter product sales rose 4%, helped by demand for cholesterol and rare disease medicines, ...